Scientists developed a laboratory test designed to detect mucormycosis, a serious fungal infection. This preclinical work evaluated a specific sandwich-ELISA method using a marker called EPS. The goal was to see if this test could accurately identify the infection in human tissue samples.
The results showed the test could successfully find the biomarker in patient tissue homogenates. It demonstrated high specificity for the pan-Mucorales group of fungi and did not cross-react with other clinically relevant yeasts or moulds. Additionally, the test's target marker remained stable under moderate heat and was insensitive to periodate treatment.
The method also worked well at low levels, detecting the marker at concentrations from picograms to low nanograms per milliliter. While this preclinical research suggests the test could serve as a helpful laboratory adjunct for diagnosing mucormycosis, it has not yet been tested in a clinical trial with human patients.
Readers should understand this is early-stage development. The study was not a clinical trial, so these findings do not yet prove the test works in real-world medical settings. More research is needed before this tool can be used to guide patient care.
